Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Prime Medicine Inc (NASDAQ: PRME) closed at $3.15 in the last session, down -3.96% from day before closing price of $3.28. In other words, the price has decreased by -$3.96 from its previous closing price. On the day, 0.5 million shares were traded. PRME stock price reached its highest trading level at $3.275 during the session, while it also had its lowest trading level at $3.09.
Ratios:
We take a closer look at PRME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.50 and its Current Ratio is at 6.50. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on December 10, 2024, initiated with a Mkt Outperform rating and assigned the stock a target price of $10.
On May 20, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
Citigroup Upgraded its Neutral to Buy on May 16, 2024, while the target price for the stock was maintained at $10.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 15 ’24 when NELSEN ROBERT bought 3,200,000 shares for $6.25 per share. The transaction valued at 20,000,000 led to the insider holds 3,200,000 shares of the business.
ARCH Venture Partners XII, LLC bought 3,200,000 shares of PRME for $20,000,000 on Feb 15 ’24. The 10% Owner now owns 3,200,000 shares after completing the transaction at $6.25 per share. On Feb 15 ’24, another insider, ARCH Venture Partners X, LLC, who serves as the 10% Owner of the company, bought 3,200,000 shares for $6.25 each. As a result, the insider paid 20,000,000 and bolstered with 3,200,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 413157152 and an Enterprise Value of 267647072. For the stock, the TTM Price-to-Sale (P/S) ratio is 516.45 while its Price-to-Book (P/B) ratio in mrq is 2.18. Its current Enterprise Value per Revenue stands at 334.559 whereas that against EBITDA is -1.292.
Stock Price History:
Over the past 52 weeks, PRME has reached a high of $9.77, while it has fallen to a 52-week low of $2.56. The 50-Day Moving Average of the stock is -6.24%, while the 200-Day Moving Average is calculated to be -33.43%.
Shares Statistics:
According to the various share statistics, PRME traded on average about 1.17M shares per day over the past 3-months and 1036990 shares per day over the past 10 days. A total of 131.16M shares are outstanding, with a floating share count of 50.89M. Insiders hold about 61.20% of the company’s shares, while institutions hold 36.06% stake in the company. Shares short for PRME as of 1734048000 were 16129538 with a Short Ratio of 13.79, compared to 1731628800 on 15189710. Therefore, it implies a Short% of Shares Outstanding of 16129538 and a Short% of Float of 23.629998999999998.
